Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249477 | 1.00 | KMT2A (0.78) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL3595931 | 1.00 | KMT2A (0.78) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL16250460 | 1.00 | KMT2A (0.78) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL1886766 | 1.00 | KMT2A (0.78) | KMT2AMEN1L3MBTL1USP2LMNA | |
| Hydrochloric Acid SCHEMBL10854308 | 0.99 | KMT2A (0.76) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL10812960 | 0.94 | KMT2A (0.72) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL11243677 | 0.89 | KMT2A (0.62) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL4274767 | 0.88 | L3MBTL1 (0.68) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL12642603 | 0.87 | KMT2A (0.80) | KMT2AMEN1L3MBTL1USP2LMNA | |
| SCHEMBL12356598 | 0.87 | KMT2A (0.80) | KMT2AMEN1L3MBTL1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822942-B1 | BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2268646-B9 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2268646-B1 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-02 | — | — | EP | disclosed |
| US-8357684-B2 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-22 | — | — | US | disclosed |
| US-8357684-B2 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-22 | — | — | US | disclosed |
| EP-2336125-B1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-08-04 | — | — | US | disclosed |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-08-04 | — | — | US | disclosed |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-06-30 | — | — | US | disclosed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| EP-0159174-B1 | SUBSTITUTED NAPHTHYRIDINE-, QUINOLINE- AND BENZOXAZINE- CARBOXYLIC ACIDS AS ANTIBACTERIAL AGENTS AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1991-10-23 | — | — | EP | disclosed |
| US-4992546-A | Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives | WARNER-LAMBERT COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
| US-4968799-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| US-4962108-A | A QUIN-4-ONE HAVING THE FOLLOWING RING SUBSTITUENTS; 1-ALKYL OR PHENYL, 3-CARBOXY DERIVATIVE, 6-FLUORO AND 8-BRIDGED N-HETEROCYCLIC RING | WARNER-LAMBERT COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| US-4923879-A | CARBOXYLIC ACID DERIVATIVES WITH BRIDGED SIDECHAINS | WARNER-LAMBERT COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0305744-A2 | Quinoline, naphthyridine and benzoxazine-carboxylic acid derivatives and their use as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4571396-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0159174-A2 | Substituted naphthyridine-, quinoline- and benzoxazine- carboxylic acids as antibacterial agents and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | KMT2A 1664/4885MEN1 4545/4885L3MBTL1 1505/4885 |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | KMT2A 1674/4885MEN1 4666/4885L3MBTL1 1560/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | KMT2A 4701/4885MEN1 4165/4885L3MBTL1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.